Free Trial
NASDAQ:AMLX

Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

Amylyx Pharmaceuticals logo
$12.69 -0.73 (-5.44%)
Closing price 04:00 PM Eastern
Extended Trading
$12.40 -0.29 (-2.29%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

Advanced

Key Stats

Today's Range
$12.34
$13.81
50-Day Range
$7.64
$14.90
52-Week Range
$2.60
$15.15
Volume
1.87 million shs
Average Volume
2.22 million shs
Market Capitalization
$1.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.75
Consensus Rating
Moderate Buy

Company Overview

Amylyx Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
53rd Percentile Overall Score

AMLX MarketRank™: 

Amylyx Pharmaceuticals scored higher than 53% of companies evaluated by MarketBeat, and ranked 672nd out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amylyx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 9 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Amylyx Pharmaceuticals has a consensus price target of $14.75, representing about 16.2% upside from its current price of $12.69.

  • Amount of Analyst Coverage

    Amylyx Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.

  • Read more about Amylyx Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($2.20) to ($1.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amylyx Pharmaceuticals is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amylyx Pharmaceuticals is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Amylyx Pharmaceuticals has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Amylyx Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.02% of the float of Amylyx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Amylyx Pharmaceuticals has recently increased by 4.28%, indicating that investor sentiment is decreasing.
  • Percentage of Shares Shorted

    11.02% of the float of Amylyx Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.
  • Change versus previous month

    Short interest in Amylyx Pharmaceuticals has recently increased by 4.28%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Amylyx Pharmaceuticals has a news sentiment score of 0.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for Amylyx Pharmaceuticals this week, compared to 5 articles on an average week.
  • Search Interest

    27 people have searched for AMLX on MarketBeat in the last 30 days. This is an increase of 350% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amylyx Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,319,495.00 in company stock.

  • Percentage Held by Insiders

    12.30% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Amylyx Pharmaceuticals' insider trading history.
Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMLX Stock News Headlines

Gold surges past $3,600 … but this has beat gold by 1,000x
Gold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns.tc pixel
See More Headlines

AMLX Stock Analysis - Frequently Asked Questions

Amylyx Pharmaceuticals' stock was trading at $3.78 at the beginning of 2025. Since then, AMLX shares have increased by 235.7% and is now trading at $12.69.

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) released its quarterly earnings results on Thursday, August, 7th. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by $0.02.
Read the conference call transcript
.

Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share.

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amylyx Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), AU Optronics (AUOTY), DiamondRock Hospitality (DRH), The RMR Group (RMR), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/07/2025
Today
10/06/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AMLX
CIK
1658551
Fax
N/A
Employees
200
Year Founded
2013

Price Target and Rating

High Price Target
$25.00
Low Price Target
$8.00
Potential Upside/Downside
+18.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
14 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$301.74 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-82.48%
Return on Assets
-70.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.72
Quick Ratio
8.72

Sales & Book Value

Annual Sales
-$249 thousand
Price / Sales
-4,473.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.40 per share
Price / Book
5.20

Miscellaneous

Outstanding Shares
89,167,000
Free Float
78,199,000
Market Cap
$1.11 billion
Optionable
Optionable
Beta
-0.33

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:AMLX) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners